

WU-KONG28

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Zhou C, Greillier L, Liu G, et al. First-line sunvozertinib in NSCLC with EGFR exon 20 insertion mutations. N Engl J Med. 2026. doi:10.1056/NEJMoa2604461




ANNENBERG CENTER FOR HEALTH SCIENCES

AT EISENHOWER

Imparting knowledge. Improving patient care.

© Copyright 2025 Annenberg Center for Health Sciences | All Rights Reserved

WU-KONG28: Sunvozertinib 300 mg Efficacy



WU-KONG28: Sunvozertinib 300 mg Safety

Adverse Events for Sunvozertinib (Grade ≥ 3)	Sunvozertinib (n=163)	Chemotherapy (n=150)
Diarrhea	87.1% (14.1%)	16.7% (0%)
Serum creatine kinase increase	58.3% (20.9%)	4% (0.7%)
Anemia	57.1% (9.2%)	62.7% (11.3%)
Rash	52.8% (0.6%)	6.7% (0%)
Paronychia	48.5% (3.7%)	0.7% (0%)
Weight decreased	43.6% (3.7%)	11.3% (0.7%)
Decreased appetite	38.7% (1.8%)	28.0% (1.3%)
Any adverse event leading to drug discontinuation Discontinuations due to TRAE	11.7% 7.4%	12% 11.3%

TRAE, treatment-related adverse events



ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

© Copyright 2025 Annenberg Center for Health Sciences | All Rights Reserved

Zhou C, et al. *N Engl J Med.* 2026